Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF (Site 1901)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Metastatic breast cancer

Running trials

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

  NCT04895358· Phase 3· Merck Sharp & Dohme LLC· Source